Natera's Signatera predicts event-free survival in phase III bladder cancer trial
NTRA•In results from the phase III VOLGA bladder cancer trial presented at the European Society for Medical Oncology Congress 2026, patients whose circulating tumor DNA cleared before surgery or remained undetectable had better event-free survival than those with persistently detectable levels.
1. Trial findings
Natera’s Signatera Genome assay featured in results from the phase III VOLGA bladder cancer trial presented at the European Society for Medical Oncology Congress 2026. Patients whose circulating tumor DNA cleared before surgery or remained undetectable had better event-free survival than those with persistently detectable levels; the findings support the assay’s potential to guide treatment decisions in muscle-invasive bladder cancer.
